Detect EGFR T790M Mutation in ctDNA of Chinese Advanced/Metastatic NSCLC Patients by Cobas, Super-ARMS, Digital PCR and NGS and Evaluate Clinical Outcomes of T790M Mutation Positive Patients Who Had AZD9291 Monotherapy

Trial Profile

Detect EGFR T790M Mutation in ctDNA of Chinese Advanced/Metastatic NSCLC Patients by Cobas, Super-ARMS, Digital PCR and NGS and Evaluate Clinical Outcomes of T790M Mutation Positive Patients Who Had AZD9291 Monotherapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Diagnostic use; Therapeutic Use
  • Acronyms ADELOS
  • Sponsors AstraZeneca
  • Most Recent Events

    • 28 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Jun 2017 According to trial design presented at 53rd Annual Meeting of the American Society of Clinical Oncology, twenty three of planned two hundred and fifty patients have been enrolled in the study as of January 2017
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top